CIK 0001422142
- Non-accelerated filer
- Smaller reporting company
Whitehawk Therapeutics, Inc.
Sign in to watch- Ticker
- WHWK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 611547850
- Phone
- +1 551-321-2234
- Business address
- 2 HEADQUARTERS PLAZA, EAST BUILDING, 11TH FLOOR, MORRISTOWN, NJ, 07960
- Former names
- Aadi Bioscience, Inc., Aerpio Pharmaceuticals, Inc., ZETA ACQUISITION CORP II
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 22 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-04-04 | Novartis Bioventures Ltd 10% owner | Sale | −47,900 | $1.01 | $48K | 5,145,208 |
| 2019-04-03 | Novartis Bioventures Ltd 10% owner | Sale | −58,033 | $0.96 | $56K | 5,193,108 |
| 2019-04-02 | Novartis Bioventures Ltd 10% owner | Sale | −51,754 | $0.97 | $50K | 5,251,141 |
| 2019-04-01 | Novartis Bioventures Ltd 10% owner | Sale | −116,909 | $0.95 | $111K | 5,302,895 |
| 2019-03-29 | Novartis Bioventures Ltd 10% owner | Sale | −63,100 | $0.91 | $57K | 5,419,804 |
| 2019-03-28 | Novartis Bioventures Ltd 10% owner | Sale | −88,835 | $0.94 | $84K | 5,482,904 |
| 2019-03-27 | Novartis Bioventures Ltd 10% owner | Sale | −50,749 | $0.99 | $50K | 5,571,739 |
| 2019-03-26 | Novartis Bioventures Ltd 10% owner | Sale | −177,762 | $1.01 | $180K | 5,622,488 |
| 2019-02-15 | PAKOLA STEVE Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2019-02-15 | Gardner Joseph H. President | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2019-02-15 | HOFFMAN STEPHEN J Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +365,000 | 365,000 | ||
| 2019-02-15 | PETERS KEVIN G. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2019-02-15 | ROGERS MICHAEL W Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +215,328 | 215,328 | ||
| 2019-01-10 | Satter Muneer A Director | Purchase | +23,818 | $2.45 | $58K | 5,621,835 |
| 2019-01-09 | Satter Muneer A Director | Purchase | +20,000 | $2.39 | $48K | 5,598,017 |
| 2019-01-08 | Satter Muneer A Director | Purchase | +20,000 | $2.20 | $44K | 5,578,017 |
| 2019-01-07 | Satter Muneer A Director | Purchase | +20,000 | $2.18 | $44K | 5,558,017 |
| 2019-01-04 | Satter Muneer A Director | Purchase | +20,000 | $2.12 | $42K | 5,538,017 |
| 2019-01-03 | Satter Muneer A Director | Purchase | +20,000 | $2.08 | $42K | 5,518,017 |
| 2019-01-02 | Satter Muneer A Director | Purchase | +20,000 | $1.94 | $39K | 5,498,017 |
Page 14 of 16 · 312 trades